Nieschlag E
Centre of Reproductive Medicine and Andrology of the University, WHO Collaboration Centre for Research in Male Reproduction, Domagkstr. 11, 48149, Münster, Germany.
Handb Exp Pharmacol. 2010(198):197-223. doi: 10.1007/978-3-642-02062-9_11.
The principle of hormonal male contraception based on suppression of gonadotropins and spermatogenesis has been established over the last three decades. All hormonal male contraceptives use testosterone, but only in East Asian men can testosterone alone suppress spermatogenesis to a level compatible with contraceptive protection. In Caucasians, additional agents are required of which progestins are favored. Current clinical trials concentrate on testosterone combined with norethisterone, desogestrel, etonogestrel, DMPA, or nestorone. The first randomized, placebo-controlled clinical trial performed by the pharmaceutical industry demonstrated the effectiveness of a combination of testosterone undecanoate and etonogestrel in suppressing spermatogenesis in volunteers.
基于抑制促性腺激素和精子发生的激素男性避孕原理在过去三十年中已得到确立。所有激素男性避孕药都使用睾酮,但只有东亚男性仅用睾酮就能将精子发生抑制到与避孕保护相适应的水平。在高加索人中,则需要额外的药物,其中孕激素是首选。目前的临床试验集中在睾酮与炔诺酮、去氧孕烯、依托孕烯、醋酸甲羟孕酮或孕二烯酮的联合使用上。制药行业进行的第一项随机、安慰剂对照临床试验证明了十一酸睾酮和依托孕烯联合使用在抑制志愿者精子发生方面的有效性。